Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aldeyra Therapeutics

3.79
-0.0800-2.07%
Post-market: 3.850.0567+1.50%19:55 EDT
Volume:2.54M
Turnover:9.70M
Market Cap:227.00M
PE:-3.92
High:4.00
Open:3.97
Low:3.74
Close:3.87
Loading ...

Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion

TIPRANKS
·
27 Jun

Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading

TIPRANKS
·
26 Jun

BRIEF-Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191

Reuters
·
26 Jun

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

THOMSON REUTERS
·
26 Jun

Aldeyra Therapeutics Inc - Clinical Trial Expected to Begin in Second Half of 2025

THOMSON REUTERS
·
26 Jun

Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships

TIPRANKS
·
23 Jun

Aldeyra Therapeutics Resubmits New Drug Application for Reproxalap to FDA for Dry Eye Disease Treatment

Reuters
·
17 Jun

Aldeyra Therapeutics Inc - No Safety Concerns Identified in Clinical Trial

THOMSON REUTERS
·
17 Jun

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

THOMSON REUTERS
·
17 Jun

Aldeyra Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
12 Jun

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Reuters
·
29 May

CORRECTED-US FDA approves Alcon's new dry-eye drug (May 28)

Reuters
·
29 May

Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating

TIPRANKS
·
21 May

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
19 May

Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships

TIPRANKS
·
19 May

BRIEF-Aldeyra Therapeutics Inc Says New Drug Application Resubmission Is Anticipated Mid‑2025

Reuters
·
06 May

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans Nda Resubmission

THOMSON REUTERS
·
06 May

Aldeyra Therapeutics Inc - New Drug Application Resubmission Is Anticipated Mid‑2025

THOMSON REUTERS
·
06 May

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Business Wire
·
06 May

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

Business Wire
·
06 May